https://doi.org/10.4081/hmr.v1i2.224

Evaluation of minimal residual disease in chronic lymphocytic leukemia

Vol. 1 No. 2: Is Elimination of Minimal Residual Disease Significant for the Outcome of CLL? The Role of Alemtuzumab
Published: May 29, 2009
Abstract Views: 287
PDF: 1191
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Matthias Ritgen
support@pagepress.org
Sebastian Böttcher
Peter Dreger
Michael Kneba
Chronic lymphocytic leukemia (CLL) is a malignancy with a variable prognosis. Poor-risk cases are characterized by advanced clinical stage, short lymphocyte doubling time, unmutated immunoglobulin heavy gene (IgVH) status, distinct genomic aberrations, ZAP70 and CD38 expression and elevated serum thymidine kinase levels. During the last decade, effective chemotherapy combinations have been developed, making high complete remission rates in this disease feasible. However, after conventional chemotherapy and autologous stem cell transplantation (SCT), all patients will eventually relapse. Nevertheless, time to progression is highly variable in patients who achieve complete clinical remissions. Therefore, minimal residual disease (MRD) undetectable by clinical means must have been present in all of these cases.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Ritgen, M., Böttcher, S., Dreger, P., & Kneba, M. (2009). Evaluation of minimal residual disease in chronic lymphocytic leukemia. Hematology Meeting Reports (formerly Haematologica Reports), 1(2). https://doi.org/10.4081/hmr.v1i2.224
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).